Prevention of cardiac hypertrophy by calcineurin inhibition: Hope or hype?

Circulation Research

Volumn 84, Issue 6, 1999, Pages 623-632

  Olson, Eric N ^a   Molkentin, Jeffery D ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Calcineurin; Cardiac hypertrophy; Cardiomyocyte; Cyclosporin; NFAT

Indexed keywords

CALCINEURIN; CALCIUM ION; PROTEIN KINASE (CALCIUM,CALMODULIN); TROPOMODULIN;

GENE EXPRESSION REGULATION; HEALTH CARE COST; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033515576     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.84.6.623     Document Type: Review

References (115)

1. Levit KR, Lazenby HC, Cown CA. National health expenditures, 1990. Health Care Finance Rev. 1991;13:29-54.
2. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13:S107-S112.
3. Chien KR, Zhu H, Knowlton KU, Miller-Hance W, van Bilsen M, O'Brien TX Evans SM. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol. 1993;55:77-95.
4. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997;59:551-571.
5. Molkentin JD, Lu J, Antos CL, Markham B, Richardson J, Robbins J, Grant S, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
6. Komuro I, Yazaki Y. Control of cardiac gene expression by mechanical stress. Annu Rev Physiol. 1993;55:55-75.
7. Watkins H, Seidman JG, Seidman CE. Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Hum Mol Genet. 1995; 4:1721-1727.
8. Vikstrom KL, Leinwand LA. Contractile protein mutations and heart disease. Curr Opin Cell Biol. 1996;8:97-105.
9. Barinaga M. Tracking down mutations that can stop the heart. Science. 1998;281:32-34.
10. Lin D, Bobkova A, Homsher E, Tobacman LS. Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. J Clin Invest. 1996;97:2842-2848.
11. Bottinelli R, Coviello DA, Redwood CS, Pellegrino MA, Maron BJ, Spirito P, Watkins H, Reggiani C. Mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res. 1997;82:106-115.
12. Charles IB, Christe ME, Aronovitz MJ, Seidman CE, Seidman JG, Mendelsohn ME. Electrophysiological abnormalities and arrhythmias in αMHC mutant familial hypertrophic cardiomyopathy mice. J Clin Invest. 1997;99:570-576.
13. 2+: implications of mutations causal for familial hypertrophic cardiomyopathy. Basic Res Cardiol. 1997;92:63-74.
14. 1-agonist-mediated phosphatidylinositide turnover and myocardial cell hypertrophy in neonatal rat myocytes. Experientia. 1990;46:81-84.
15. Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Circ Res. 1993;73:424-438.
16. Leite MF, Page E, Ambler SK. Regulation of ANP secretion by endothelin-1 in cultured atrial myocytes: desensitization and receptor subtype. Am J Physiol. 1994;267:H2193-H2203.
17. Marban E, Kitakaze M, Kusuoka H, Porterfield JK, Yue DT, Chacko VP. Intracellular free calcium concentrations measured with 19F NMR spectroscopy in intact ferret hearts. Proc Natl Acad Sci U S A. 1987;84: 6005-6009.
18. Bustamante JO, Ruknudin A, Sachs F. Stretch-activated channels in heart cells: relevance to cardiac hypertrophy. J Cardiovasc Pharmacol. 1991;17:S110-S113.
19. LeGuennec JY, White E, Grannier F, Argibay JA, Garnier D. Stretch-induced increase of resting intracellular calcium concentration in single guinea-pig ventricular myocytes. Exp Physiol. 1991;6:975-978.
20. Saeki Y, Kurihara S, Hongo K, Tanaka E. Tension and intracellular calcium transient of activated ferret ventricular muscle in response to step length changes. Adv Exp Med Biol. 1993;332:639-647.
21. Perreault CL, Shannon RP, Shen YT, Vatner SF, Morgan JP. Excitation-contraction coupling in isolated myocardium from dogs with compensated left ventricular hypertrophy. Am J Physiol. 1994;266: H2436-H2442.
22. 2+ transient in ferret ventricular muscles during hypoxia and acidosis. Am J Physiol. 1995;269: C690-C697.
23. Balke CW, Shorofsky SR. Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc Res. 1998;37:290-299.
24. Herzig TC, Jobe SM, Aoki H, Molkentin JD, Cowley AW, Izumo S, Markham B. E. Angiotensin II type 1a receptor gene expression in the heart: AP-1 and GATA-4 mediate the response to pressure overload. Proc Natl Acad Sci U S A. 1997;94:7543-7548.
25. Hasegawa K, Lee, SJ, Jobe SM, Markham BE, Kitsis RN. cis-acting sequences that mediate induction of the α-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction. Circulation. 1997;96:3943-3953.
26. Molkentin JD, Olson EN. GATA4: a novel transcriptional regulator of cardiac hypertrophy? Circulation. 1997;96:3833-3835.
27. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997;15:707-747.
28. McCaffrey PG, Luo C, Kerppola TK, Jain J, Badalian TM, Ho AM, Burgeon E, Lane WS, Lambert JN, Curran T, Verdine GL, Rao A, Hogan PG. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. Science. 1993;262:750-754.
29. Northrop JP, Ho SN, Chen L, Thomas DJ, Timmerman LA, Nolan GP, Admon A, Crabtree GR. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature. 1994;369: 497-502.
30. Ho SN, Thomas DJ, Timmerman LA, Li X, Francke U, Crabtree GR. NFATc3, a lymphoid-specific NFATc family member that is calcium-regulated and exhibits distinct DNA binding specificity. J Biol Chem. 1995;270:19898-19907.
31. Hoey T, Sun YL, Williamson K, Xu X. Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins. Immunity. 1995;2:461-472.
32. Masuda ES, Naito Y, Tokumitsu H, Campbell D, Saito F, Hannum C, Aral K-I, Arai N. NFATx, a novel member of the nuclear factor of activated T cells family that is expressed predominately in the thymus. Mol Cell Biol. 1995;15:2697-2706.
33. Park J, Takeuchi A, Sharma S. Characterization of a new isoform of the NFAT (nuclear family of activated T cells) gene family member NFATc. J Biol Chem. 1996;271:20914-20921.
34. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature. 1991;352:803-807.
35. Loh C, Carew JA, Kim J, Hogan PG, Rao A. T-cell receptor stimulation elicits an early phase of activation and a later phase of deactivation of the transcription factor NFAT1. Mol Cell Biol. 1996;16:3945-3954.
36. Loh C, Shaw KT, Carew J, Viola JPB, Lou C, Perrino BA, Rao A. Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. J Biol Chem. 1996;271:10884-10891.
37. Rooney JW, Hodge MR, McCaffrey PG, Rao A, Glimcher LG. A common factor regulates both Th1-and The-specific cytokine gene expression. EMBO J. 1994;13:625-633.
38. Wolfe SA, Zhou P, Dotsch V, Chen L, You A, Ho SN, Crabtree GR, Wagner G, Verdine GL. Unusual Rel-like architecture in the DNA-binding domain of the transcription factor NFATc. Nature. 1997;385: 172-176.
39. Stemmer PM, Klee CB. Dual calcium ion regulation of calcineurin by calmodulin and calcineurin B. Biochemistry. 1994;33:6859-6866.
40. Su Q, Zhao M, Weber E, Eugster HP, Ryffel B. Distribution and activity of calcineurin in rat tissues: evidence for post-transcriptional regulation of testis-specific calcineurin B. Eur J Biochem. 1995;230:469-474.
41. Zhang BW, Zimmer G, Chen J, Ladd D, Li E, Alt FW, Wiederrecht G, Cryan J, O'Neill EA, Siedman CE, Abbas AK, Seidman JG. T cell responses in calcineurin A α-deficient mice. J Exp Med. 1996;183: 413-420.
42. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science. 1991;251:283-287.
43. Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science. 1989;246:1617-1620.
44. Sadoshima J, Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro: potential role of 70-kd S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res. 1995;77:1040-1052.
45. 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes: evidence for involvement of p70 S6 kinase. Circ Res. 1997;81:176-185.
46. Grepin C, Dagnino LL, Robitaille L, Haberstroh LL, Antakly T, Nemer M. A hormone-encoding gene identifies a pathway for cardiac but not skeletal muscle gene transcription. Mol Cell Biol. 1994;14:3115-3129.
47. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA. FK506-and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature. 1992;357:692-694.
48. Graver CL, DeMayo F, Goldstein MA, Means AR. Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice. Endocrinology. 1993;133:376-388.
49. 2+ response amplitude and duration. Nature 1997;386:855-858.
50. Chin E, Olson EN, Yang Q, Shelton J, Bassel-Duby R, Williams RS. A calcineurin dependent pathway controls skeletal muscle fiber type. Genes Dev. 1998;12:2499-2509.
51. 2+ flux. Cell. 1995;83: 463-472.
52. 2+ release channel closure in rat heart. J Physiol. 1997;500:343-354.
53. Liu S, Liu P, Borras A, Chatila T, Speck SH. Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member. EMBO J. 1997;16:143-153.
54. Black BL, Olson EN. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol. 1998;14:167-196.
55. Bogoyevitch MA, Sugden PH. The role of protein kinases in adaptational growth of the heart. Int J Biochem Cell Biol. 1996;28:1-12.
56. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest. 1997;100: 2189-2195.
57. 1-adrenergic induction of the skeletal α-actin promoter during cardiac myocyte hypertrophy. J Biol Chem. 1995;270:410-417.
58. Bourinet E, Fournier F, Lory P, Charnet P, Nargeot J. Protein kinase C regulation of cardiac calcium channels expressed in Xenopus oocytes. Pflugers Arch. 1992;421:247-255.
59. Venema RC, Kuo JF. Protein kinase C-mediated phosphorylation of troponin I and C-protein in isolated myocardial cells is associated with inhibition of myofibrillar actomyosin MgATPase. J Biol Chem. 1993; 268:2705-2711.
60. Jideama NM, Noland TA Jr, Raynor RL, Blobe GC, Fabbro D, Kazanietz MG, Blumberg PM, Hannun YA, Kuo JF. Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties. J Biol Chem. 1996;271:23277-23282.
61. Zamponi GW, Bourinet E, Nelson D, Nargeot J, Snutch TP. Crosstalk between G proteins and protein kinase C mediated by the calcium channel alpha 1 subunit. Nature. 1997;38:442-446.
62. 2+ /calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression in ventricular myocytes. J Biol Chem. 1997;272:31203-31208.
63. Sei CA, Irons CE, Sprenkle AB, McDonough PM, Brown JH, Glembotski CC. The α-adrenergic stimulation of atrial natriuretic factor expression in cardiac myocytes requires calcium influx, protein kinase C, and calmodulin-regulated pathways. J Biol Chem. 1991;266: 15910-15916.
64. McDonough PM, Glembotski CC. Induction of atrial natriuretic factor and myosin light chain-2 gene expression in cultured ventricular myocytes by electrical stimulation of contraction. J Biol Chem. 1992; 267:11665-11668.
65. Clerk A, Michael A, Sugden PH. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J Cell Biol. 1998;142:523-535.
66. Lazou A, Bogoyevitch MA, Clerk A, Fuller SJ, Marshall CJ, Sudgen PH. Regulation of mitogen-activated proteins kinase cascade in adult rat heart preparations in vitro. Circ Res. 1994;75:932-941.
67. Thornburn J, Carlson M, Mansour SJ, Chien KR, Ahn NG, Thornburn A. Inhibition of a signaling pathway in cardiac muscle cells by active mitogen-activated protein kinase kinase. Mol Biol Cell. 1995;6: 1479-1490.
68. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiro Y, Mizuno T, Maemura K, Kurihara H, Aikawa R, Takano H, Yazaki Y. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem. 1996;271:3221-3228.
69. Glennon PE, Kaddoura S, Sale EM, Sale GJ, Fuller SJ, Sugden PH. Depletion of mitogen-activated protein kinase using an antisense oligonucleotide approach downregulates the phenylephrine-induced hypertropic response in rat cardiac myocytes. Circ Res. 1996;78:954-961.
70. 2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res. 1997; 80:139-146.
71. Force T, Pombo CM, Avruch JA, Bonventre JV, Kyriakis JM. Stress-activated protein kinases in cardiovascular disease. Circ Res. 1996;78: 947-953.
72. Bogoyevitch MA, Anderson MB, Gillespie-Brown J, Clerk A, Glennon PE, Fuller SJ, Sugden PH. Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Biochem J. 1996;314:115-121.
73. Zechner D, Thuerauf DJ, Hanford DS, McDonough PM, Glembotski CC. A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol. 1997;139:115-127.
74. Wang Y, Huanf S, Sah VP, Ross J, Heller Brown J, Han J, Chien KR. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 1998;273:2161-2168.
75. Ramirez MT, Sah VP, Zhao XL, Hunter JJ, Chien KR, Brown JH. The MEKK-JNK pathway is stimulated by α1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J Biol Chem. 1997;272:14057-14061.
76. 2-terminal kinase in ventricular muscle cells. J Biol Chem. 1998;272:5423-5426.
77. Nemoto S, Sheng Z, Lin A. Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy. Mol Cell Biol. 1998;18:3518-3526.
78. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem. 1995;270:23173-23178.
79. Li WG, Zaheer A, Coppey L, Oskarsson HJ. Activation of JNK in the remote myocardium after large myocardial infarction in rats. Biochem Biophys Res Commun. 1998;246:816-820.
80. Izumi Y, Kim S, Murakami T, Yamanaka S, Iwao H. Cardiac mitogen-activated protein kinase activities are chronically increased in stroke-prone hypertensive rats. Hypertension. 1998;31:50-56.
81. Rockman, HA, Koch WJ, Lefkowitz RJ. Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. Am J Physiol. 1997;272:H1553-H1559.
82. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, Lefkowitz RJ. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or beta ARK inhibitor. Science. 1995;268: 1350-1353.
83. Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Borg J, Perriard JC, Chien KR, Caroni P. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 1997;88:393-403.
84. Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross J Jr, Lefkowitz RJ, Koch WJ. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A. 1998;95:7000-7005.
85. Genot E, Cleverley S, Henning S, Cantrell D. Multiple p21ras effector pathways regulate nuclear factor of activated T cells. EMBO J. 1996; 15:3923-3933.
86. Jain J, Miner Z, Rao A. Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. J Immunol. 1993;151:837-848.
87. Jain J, Nalefski EA, McCaffrey PG, Johnson RS, Speigelman BM, Papaioannou V, Rao A. Normal peripheral T-cell function in c-Fos-deficient mice. Mol Cell Biol. 1994;14:1566-1574.
88. Northrop JP, Ullman KS, Crabtree GS. Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NF-AT) complex. J Biol Chem. 1993;268:2917-2923.
89. Boise LH, Petryniak B, Mao X, June CH, Wang C, Lindstein T, Bravo R, Kovary K, Leiden JM, Thompson CB. The NFAT-1 DNA binding complex in activated T cells contains fra-land junB. Mol Cell Biol. 1993;13:1911-1919.
90. Werlen G, Jacinto E, Xia Y, Karin M. Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. EMBO J. 1998;17:3101-3111.
91. 2+ /calmodulin kinase type IV/Gr. J Exp Med. 1996;184:101-112.
92. ras and calcineurin synergize to regulate the nuclear factor of activated T cells. J Exp Med. 1993;178: 1517-1522.
93. James J, Robbins J. Molecular remodeling of cardiac contractile function. Am J Physiol. 1997;273:H2105-H218.
94. Sussman MA, Welch S, Cambon N, Klevitsky R, Hewett TE, Price R, Witt SA, Kimball TR. Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice. J Clin Invest. 1998;101:51-61.
95. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, Gualberto A, Wieczorek DF, Molkentin JD. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 1998; 281:1690-1693.
96. q leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci U S A. 1998;95: 13893-13898.
97. Maron BJ, Gardin JM, Flack JM, Gidding SS, Bild D. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785-789.
98. 2+ handling in isolated rat myocardium. Am J Physiol. 1998;274:H1361-H1370.
99. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, Vatner SF. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res. 1999;84:735-740.
100. Muller JG, Nemoto S, Laser M, Carabello BA, Menick DR. Calcineurin inhibition and cardiac hypertrophy. Science. 1998;282:1007.
101. Luo Z, Shyu K-G, Gualberto A, Walsh K. Calcineurin inhibitors and cardiac hypertrophy. Nat Med. 1998;4:1092-1093.
102. Zhang W, Kowal RC, Rusnak FR, Sikkink RA, Olson EN, Victor RG. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res. 1999;84:722-728.
103. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
104. Susic D, Nunez E, Frohlich ED. Reversal of hypertrophy: an active biologic process. Curr Opin Cardiol. 1995;10:466-472.
105. Lim HW, Molkentin JD. Calcineurin and human heart failure. Nat Med. In press.
106. Gheorghiade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO. Current medical therapy for advanced heart failure. Am Heart J. 1998;135(6 pt 2, suppl):S231-S248.
107. O'Connor CM, Gattis WA, Swedberg K. Current and novel pharmacologic approaches in advanced heart failure. Am Heart J. 1998;135(6 pt 2 suppl):S249-S263.
108. Haverich A, Costard-Jackle A, Cremer J, Herrmann G, Simon R. Cyclosporin A and transplant coronary disease after heart transplantation: facts and fiction. Transplant Proc. 1994;26:2713-2715.
109. Atkison P, Joubert G, Barron A, Grant D, Paradis K, Seidman E, Wall W, Rosenberg H, Howard J, Williams S, Stiller C. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet. 1995;345:894-896.
110. Chang RK, Alzona M, Alejos J, Jue K, McDiarmid SV. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. Am J Cardiol. 1998;81:1277-1280.
111. Reid CJ, Yacoub MH. Determinants of left ventricular function one year after cardiac transplantation. Br Heart J. 1988;5:397-402.
112. Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med. 1996;2:299-305.
113. Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science. 1997;275:1930-1933.
114. Chow C-W, Rincon M, Cavanagh J, Dickens M, Davis RJ. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science. 1997;278:1638-1641.
115. Zhu J, Shibasaki F, Price R, Guillemot JC, Yano T, Dotsch V, Wagner G, Ferrara P, McKeon F. Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1. Cell. 1998;93: 851-861.